Results of carbon ion radiotherapy for skin carcinomas in 45 patients
文献类型:期刊论文
作者 | Zhang, H1,2,3![]() ![]() ![]() ![]() ![]() |
刊名 | BRITISH JOURNAL OF DERMATOLOGY
![]() |
出版日期 | 2012 |
卷号 | 166页码:1100-1106 |
ISSN号 | 0007-0963 |
DOI | 10.1111/j.1365-2133.2011.10764.x |
英文摘要 | Background Heavy ions represent the best tool for external radiotherapy (RT) of inoperable tumours. Heavy ion RT has been used in the treatment of various tumours, especially for radioresistant tumours mediated by hypoxia, localized near organs at risk. Most of these treatments are concentrated in deep-seated tumours such as those of the brain, head, lung, liver, rectum and urogenital organs, and treatment of skin carcinomas is limited. Objectives To evaluate the outcome and toxicity after carbon ion RT for skin carcinomas at the Heavy Ion Research Facility in Lanzhou, China. Methods Between November 2006 and March 2009, 45 patients with skin carcinoma [squamous cell carcinoma (SCC) (n = 16), basal cell carcinoma (BCC) (n = 12), malignant melanoma (MM) (n = 7), Bowen disease (n = 8) and Paget disease (n = 2)] were treated with carbon ion RT within a clinical Phase I trial. Patients received total doses of 60-70 GyE for SCC and BCC, 61-75 GyE for MM, 60 GyE for Bowen disease and 42 5 GyE for Paget disease, administered in 6-11 fractions over 6-11 days, with a fraction dose of 7-10 GyE. Results The mean follow-up was 24 months, range 12-36 months. The actuarial local control rates at 1 and 3 years were 90.9% and 65.5% for SCC, 91.7% and 80.2% for BCC, 85.7% and 42.9% for MM, 90% and 90% for Bowen and Paget diseases, respectively. The actuarial 1- and 3-year overall survival rates for 45 patients were 88 9% and 86%, respectively. No severe side-effects greater than Common Toxicity Criteria grade 3 have been observed. Conclusions The results demonstrated that heavy ion RT offers high local tumour control and progression-free survival rates without significant radiation-induced toxicity for patients with skin carcinomas. |
WOS关键词 | EXTRAMAMMARY PAGETS-DISEASE ; MALIGNANT-MELANOMA ; BASAL-CELL ; PROTON RADIOTHERAPY ; RADIATION-THERAPY ; CANCER ; SURGERY ; IRRADIATION ; MANAGEMENT ; EXCISION |
资助项目 | Key Scientific Technology Research Projects of Gansu Province[O702NKDA045] ; Key Scientific Technology Research Projects of Gansu Province[O801NKDA001] ; Key Scientific Technology Research Projects of Gansu Province[O92NKDA034] |
WOS研究方向 | Dermatology |
语种 | 英语 |
WOS记录号 | WOS:000304661600029 |
出版者 | WILEY-BLACKWELL |
资助机构 | National Basic Research Program of China (973 Program) ; National Basic Research Program of China (973 Program) ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; Key Scientific Technology Research Projects of Gansu Province ; Key Scientific Technology Research Projects of Gansu Province |
源URL | [http://ir.impcas.ac.cn/handle/113462/23416] ![]() |
专题 | 近代物理研究所_实验物理中心 近代物理研究所_兰州重离子研究装置 中国科学院近代物理研究所 |
通讯作者 | Zhang, H (reprint author), Chinese Acad Sci, Inst Modern Phys, Dept Heavy Ion Radiat Med, Lanzhou 730000, Peoples R China. |
作者单位 | 1.Chinese Acad Sci, Inst Modern Phys, Dept Heavy Ion Radiat Med, Lanzhou 730000, Peoples R China 2.Chinese Acad Sci, Key Lab Heavy Ion Radiat Biol & Med, Lanzhou 730000, Peoples R China 3.Key Lab Heavy Ion Radiat Med Gansu Prov, Lanzhou 730000, Peoples R China 4.Gen Hosp Lanzhou Command, Dept Radiotherapy, Lanzhou 730050, Peoples R China 5.Tumour Hosp Gansu Prov, Dept Radiotherapy, Lanzhou 730050, Peoples R China |
推荐引用方式 GB/T 7714 | Zhang, H,Li, S,Wang, XH,et al. Results of carbon ion radiotherapy for skin carcinomas in 45 patients[J]. BRITISH JOURNAL OF DERMATOLOGY,2012,166:1100-1106. |
APA | Zhang, H.,Li, S.,Wang, XH.,Li, Q.,Wei, SH.,...&Zhang, H .(2012).Results of carbon ion radiotherapy for skin carcinomas in 45 patients.BRITISH JOURNAL OF DERMATOLOGY,166,1100-1106. |
MLA | Zhang, H,et al."Results of carbon ion radiotherapy for skin carcinomas in 45 patients".BRITISH JOURNAL OF DERMATOLOGY 166(2012):1100-1106. |
入库方式: OAI收割
来源:近代物理研究所
浏览0
下载0
收藏0
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。